Valuation: Singular Genomics Systems, Inc.

Market Cap 49.23M 42.93M 40.54M 36.81M 68.96M 4.72B 69.25M 486M 187M 2.4B 185M 181M 7.73B P/E 2022
-1.57x
P/E 2023 -0.35x
Enterprise Value -50.88M -44.37M -41.89M -38.04M -71.28M -4.88B -71.57M -502M -194M -2.48B -191M -187M -7.99B EV / Sales 2022
-56,007,684x
EV / Sales 2023 -22,792,100x
Free-Float
84.03%
Yield 2022 *
-
Yield 2023 -
3 years 5.34
Extreme 5.34
23.41
5 years 5.34
Extreme 5.34
533.1
10 years 5.34
Extreme 5.34
1,001.1
Manager TitleAgeSince
Chief Executive Officer - 28/04/2026
Chief Operating Officer 67 01/09/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 40 21/02/2025
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
2/21/25 A Issuer sale

Director

360,887 14.2248%
2/21/25 A Issuer sale

Director

6,783 0.2674%
2/21/25 A Issuer sale

Director

22,139 0.8726%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-.--%-.--%+76.08% 50.7M
-1.04%+6.83%+35.84%+28.05% 241B
-0.32%+5.83%+9.58%-17.01% 149B
+2.55%+6.55%-10.35%+31.26% 139B
-0.48%+0.84%-55.70%-18.27% 62.81B
+0.01%+4.61%+18.61%+20.87% 50.87B
-1.69%-1.20%-19.89%-15.39% 48.21B
+0.08%+6.49%+23.87%+39.32% 44.11B
-1.88%+3.25%+40.14%+53.16% 41.42B
-2.27%+16.07%+133.21%+70.51% 36.18B
Average -0.48%+5.78%+17.53%+26.86% 81.24B
Weighted average by Cap. -0.26%+6.14%+15.57%+17.52%

Financials

2022 2023
Net sales 0.76 0.67 0.63 0.57 1.07 73.41 1.08 7.55 2.91 37.32 2.87 2.81 120.08 2.91 2.54 2.4 2.18 4.08 279.33 4.09 28.71 11.08 142.01 10.94 10.69 456.94
Net income -90.88M -79.25M -74.83M -67.95M -127M -8.72B -128M -896M -346M -4.43B -341M -334M -14.27B -94.82M -82.68M -78.07M -70.9M -133M -9.1B -133M -935M -361M -4.63B -356M -348M -14.88B
Net Debt -186M -162M -153M -139M -261M -17.88B -262M -1.84B -709M -9.09B -700M -684M -29.25B -100M -87.3M -82.43M -74.85M -140M -9.61B -141M -987M -381M -4.88B -376M -368M -15.71B
Logo Singular Genomics Systems, Inc.
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
Employees
255
  1. Stock Market
  2. Stocks
  3. OMIC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!